NCT06855615View on ClinicalTrials.gov

Comparison of Thrice-Daily Premixed Human Insulin with Basal-Bolus Therapy Among Patients with Poorly Controlled Type 2 Diabetes Mellitus

PHASE4CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

January 14, 2021

Study Completion Date

July 1, 2021

Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
DRUG

Mixtard® 30 TDS

The clinical use of TDS premixed human insulin (PHI) is unclear. In contrast, biphasic insulin analogue given thrice daily is a well-proven, safe and suitable alternative to an intensified insulin regimen.

DRUG

Insulatard® once daily and thrice daily prandial Actrapid®

Basal bolus regimen is considered a physiological form of treatment and the standard of care in clinical practice but the multiple daily injections often lead to poor compliance.

Trial Locations (1)

10450

Hospital Pulau Pinang, George Town

All Listed Sponsors
collaborator

Penang Hospital, Malaysia

OTHER_GOV

lead

Hospital Sultanah Aminah Johor Bahru

OTHER_GOV

NCT06855615 - Comparison of Thrice-Daily Premixed Human Insulin with Basal-Bolus Therapy Among Patients with Poorly Controlled Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter